Epigral Ltd (EPIGRAL) Price & Analysis

Compare

1 Followers

EPIGRAL Stock Chart & Stats

₹1244.30

-₹4.30(-0.24%)

At close: Jan 09 4:00 PM EST

₹1244.30

-₹4.30(-0.24%)

Day’s Range― - ―

52-Week Range₹822.05 - ₹2,114.30

Previous CloseN/A

Volume42.70K

Average Volume (3M)1.86K

Market Cap

₹38.20B

Enterprise Value₹43.01B

Total Cash (Recent Filing)₹952.40M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)33.6

Beta1.47

Next Earnings

Apr 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.46%

Share Statistics

EPS (TTM)9.10

Shares Outstanding43,141,340

10 Day Avg. Volume1,295

30 Day Avg. Volume1,859

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)4.21

Price to Sales (P/S)3.14

P/FCF Ratio32.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)58.4

Revenue Forecast (FY)₹24.75B

Bulls Say, Bears Say

Bulls Say

Free Cash Flow TurnaroundEpigral’s shift to positive free cash flow and strong operating cash conversion is a durable strength: it funds capex, supports deleveraging and working capital needs, and reduces external financing reliance. This persistent cash generation improves resilience and strategic optionality over months.

Healthy Margins & Operational EfficiencySustained healthy gross and EBITDA margins indicate structural pricing power and operational efficiency in chlor-alkali and derivatives. Consistent margins support reinvestment in downstream capabilities and buffer input cost swings, helping earnings durability across cycles over the coming months.

Integrated Chlor‑Alkali + Downstream ModelVertical integration that monetizes co-products and produces value‑added derivatives reduces reliance on commodity spreads and disposal costs. This diversification across downstream products and industrial end markets stabilizes revenue mix and enhances long‑term margin capture versus pure commodity exposure.

Bears Say

Substantial Total DebtDespite improved leverage ratios, a sizeable absolute debt stock is a lasting constraint: it increases interest expense sensitivity, limits strategic investments and raises refinancing risk if markets tighten. Managing this debt load is a multi‑quarter structural priority for stability.

Volatile Revenue GrowthIntermittent revenue swings reflect sensitivity to end‑market cycles and utilization; this unpredictability complicates forward planning, capex timing and margin stability. Over the next several months, revenue volatility can materially affect cash flows and earnings visibility.

Input Cost Exposure (Power & Salt)Epigral’s profitability materially depends on power and salt cost spreads versus product prices. Structural swings in these inputs can compress margins quickly; limited control over these commodity inputs is a persistent operational risk affecting medium‑term margin resilience.

Epigral Ltd News

Epigral Board Clears Q3 and Nine-Month FY25 Unaudited Results

Epigral Ltd ( ($IN:EPIGRAL) ) has provided an announcement. Epigral Limited reported that its board of directors met...

1M ago

Epigral’s Q3 Profit Slides on Margin Pressure as Capex-Led Growth Plans Stay on Track

Epigral Ltd ( ($IN:EPIGRAL) ) has shared an update. Epigral Limited reported Q3 FY26 revenue of ₹603 crore,...

1M ago

Epigral Releases Investor Presentation on Q3 FY26 Unaudited Results

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an update. Epigral Limited has notified the stock exchanges that it...

1M ago

Epigral Plans One-on-One VC Meet With UTI AMC on 16 January

Epigral Ltd ( ($IN:EPIGRAL) ) has shared an update. Epigral Ltd has notified stock exchanges that it will...

2M ago

Epigral to Hold One-on-One Virtual Meeting With Bandhan Mutual Fund

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an update. Epigral Limited has notified the stock exchanges that it...

3M ago

Epigral Limited Schedules Investor Meeting with VLS Finance

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an announcement. Epigral Limited has announced a one-on-one meeting with VLS...

4M ago

Epigral Limited Schedules Q2 FY26 Results Conference Call

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has announced a conference call scheduled for...

4M ago

Epigral Limited Confirms Compliance with SEBI Regulations for Q3 2025

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has submitted a confirmation certificate under Regulation...

5M ago

Epigral Limited Releases Q1 FY26 Earnings Call Transcript

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has released the transcript of its Q1...

7M ago

Epigral Limited Schedules Investor Meeting with EverFlow Partners

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an update. Epigral Limited has announced a one-on-one virtual meeting with...

7M ago

EPIGRAL FAQ

What was Epigral Ltd’s price range in the past 12 months?

Epigral Ltd lowest stock price was ₹822.05 and its highest was ₹2114.30 in the past 12 months.

What is Epigral Ltd’s market cap?

Epigral Ltd’s market cap is ₹38.20B.

When is Epigral Ltd’s upcoming earnings report date?

Epigral Ltd’s upcoming earnings report date is Apr 27, 2026 which is in 45 days.

How were Epigral Ltd’s earnings last quarter?

Epigral Ltd released its earnings results on Jan 30, 2026. The company reported ₹9.1 earnings per share for the quarter, beating the consensus estimate of ₹7.3 by ₹1.8.

Is Epigral Ltd overvalued?

According to Wall Street analysts Epigral Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Epigral Ltd pay dividends?

Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here

What is Epigral Ltd’s EPS estimate?

Epigral Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Epigral Ltd have?

Epigral Ltd has 43,141,340 shares outstanding.

What happened to Epigral Ltd’s price movement after its last earnings report?

Epigral Ltd reported an EPS of ₹9.1 in its last earnings report, beating expectations of ₹7.3. Following the earnings report the stock price went up 0.894%.

Which hedge fund is a major shareholder of Epigral Ltd?

Currently, no hedge funds are holding shares in IN:EPIGRAL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Epigral Ltd

Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.